PFE catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 2NCT04430738Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersSeagen, a wholly owned subsidiary of Pfizer · Colorectal CarcinomaActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Jul 31, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04553133PF-07104091 as a Single Agent and in Combination TherapyPfizer · Small Cell Lung CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04579380Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsSeagen, a wholly owned subsidiary of Pfizer · Uterine NeoplasmsActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Nov 1, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04721977A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced...Pfizer · Breast CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Jul 17, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT07228390A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the...Pfizer · Hidradenitis SuppurativaActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05217446A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously...Pfizer · Metastatic Colorectal CancerActive, not recruitingPFELeadLLYCollaboratorMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 19, 2026Actual
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.